Bacterial immunotherapy shows promise in tumor-targeting
A nonvirulent tumor-targeting bacterial strain bioengineered to release multiple Toll-like receptor (TLR) ligands was shown to suppress tumor growth and prolong survival in mouse tumor models in a Korean study, suggesting it could be a new cancer immunotherapy in humans.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST